AU2013203559B2 — Oral formulations and lipophilic salts of methylnaltrexone
Assigned to Wyeth LLC · Expires 2015-12-03 · 10y expired
What this patent protects
The present invention provides compositions comprising methylnaltrexone or a salt thereof, and compositions and formulations thereof, for oral administration. WO 2011/112816 PCT/US2O1 1/027913 C/)N a) :, co ~' C-Q LO ca- LO Z) LO CO~ o oO CC) co) cfco co C:> co Cco C:CN CNt co…
USPTO Abstract
The present invention provides compositions comprising methylnaltrexone or a salt thereof, and compositions and formulations thereof, for oral administration. WO 2011/112816 PCT/US2O1 1/027913 C/)N a) :, co ~' C-Q LO ca- LO Z) LO CO~ o oO CC) co) cfco co C:> co Cco C:CN CNt coo 0 00 C.0000000l asGSeGeGl %
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.